Company Description

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.

Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.

The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

NKGen Biotech, Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	63
CEO	Paul Y. Song

Contact Details

Address: 3001 Daimler Street Santa Ana, California 92705 United States
Phone	949-396-6830
Website	nkgenbiotech.com

Stock Details

Ticker Symbol	NKGN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001845459
ISIN Number	US65488A1016
SIC Code	2836

Key Executives

Name	Position
Dr. Paul Y. Song M.D.	Chief Executive Officer and Chairman
Dr. Yong Man Kim Ph.D.	Chief Scientific Officer
James A. Graf	Interim Chief Financial Officer
Yoonmi Kang	SVice President of Technical Ops and Development
Irene Chang	SVice President, Human Resources and Corporate Culture
Denise A. Chua CLS, MBA, MT (ASCP)	SVice President of Corporate Affairs
Ryan Park C.F.A.	Executive Vice President of Financial Planning and Analysis and Corporate Strategy

Latest SEC Filings

Date	Type	Title
Dec 12, 2024	8-K	Current Report
Dec 4, 2024	8-K	Current Report
Dec 2, 2024	8-K	Current Report
Nov 26, 2024	8-K	Current Report
Nov 15, 2024	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Nov 12, 2024	8-K	Current Report
Oct 30, 2024	8-K	Current Report
Oct 24, 2024	8-K	Current Report
Oct 10, 2024	8-K	Current Report
Oct 4, 2024	8-K	Current Report

View All SEC Filings